Clinical trial begins for new COVID-19 treatment

lab
Credit: CC0 Public Domain

The University of Rochester Medical Center (URMC) is participating in a NIH-sponsored clinical trial to evaluate the safety and efficacy of the investigational antiviral drug remdesivir in hospitalized adults diagnosed with COVID-19. The study is being led by Ann R. Falsey, M.D., and Angela R. Branche, M.D., with the URMC Vaccine Trials and Evaluation Unit (VTEU).

Remdesivir, developed by Gilead Sciences, is a broad-spectrum antiviral treatment that has been previously tested in humans with the Ebola virus and has shown promise in animal models for treating Middle East respiratory syndrome (MERS) and (SARS), which are caused by other coronaviruses. It is believed that the drug blocks a particular enzyme that is required for viral replication.

The double-blind, placebo-controlled trial will involve acute COVID-19 inpatients at Strong Memorial Hospital. The study may be expanded over time to include additional investigational antiviral treatments.

The URMC VTEU was established with support from the National Institute of Allergy and Infectious Diseases to conduct of vaccines, treatments, and diagnostics for known and emergent infectious threats. URMC is one of only nine VTEU sites in the U.S.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

Citation: Clinical trial begins for new COVID-19 treatment (2020, April 1) retrieved 4 June 2020 from https://medicalxpress.com/news/2020-04-clinical-trial-covid-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments